NCT06275269 Endoscopic Mucosal Injection Versus Ultrasound-Guided Injection of Triamcinolone to Treat Subglottic Stenosis
| NCT ID | NCT06275269 |
| Status | Recruiting |
| Phase | — |
| Sponsor | China-Japan Friendship Hospital |
| Condition | Subglottic Stenosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-03-10 |
| Primary Completion | 2025-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2024-03-10 with a primary completion date of 2025-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study employs a multicenter, randomized controlled trial method, where patients meeting the inclusion criteria for subglottic stenosis are randomly divided into two groups. These groups are respectively undergoing translaryngeal endoscopic mucosal injection and ultrasound-guided injection of triamcinolone treatment. The comparison will focus on various indicators such as therapeutic effect, incidence of adverse reactions, treatment costs, and hospital resource utilization between the two groups. The safety and effectiveness will be compared to determine the relative merits of the two treatment methods.
Eligibility Criteria
Inclusion Criteria: * 1: "Diagnosed with subglottic stenosis through laryngoscopic examination or imaging studies such as CT." * 2: "Experiencing symptoms related to subglottic stenosis, such as breathing difficulties, hoarseness, etc." Exclusion Criteria: * 1: "Severe cardiopulmonary dysfunction, patients extremely debilitated and unable to tolerate the procedure." * 2: "Patients allergic to lidocaine, midazolam, triamcinolone, or any of their components." * 3: "Pregnant or lactating women." * 4: "Unstable angina, congestive heart failure, severe bronchial asthma." * 5: "Severe hypertension and arrhythmias, hemodynamically unstable, and severe respiratory failure (PaO2 \<60mmHg after oxygen therapy or mechanical ventilation)." * 6: "Known coagulation dysfunction, inability to stop anticoagulants, antiplatelet agents, aspirin, or nonsteroidal anti-inflammatory drugs before treatment." * 7: "Patients do not agree to participate in this study." * 8: "Participation in other studies within the last three months and not withdrawn or concluded, or having received triamcinolone treatment less than 1 month ago." * 9: "Researchers believe there are any circumstances making the patient unsuitable for inclusion."
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06275269 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Subglottic Stenosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06275269 currently recruiting?
Yes, NCT06275269 is actively recruiting participants. Contact the research team at hougangcmu@163.com for enrollment information.
Where is the NCT06275269 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06275269 clinical trial?
NCT06275269 is sponsored by China-Japan Friendship Hospital. The trial plans to enroll 40 participants.